England’s obesity drug uptake exposes affordability gap as NHS rollout begins

Overview

The Conversation reports that private prescribing of obesity drugs Wegovy (semaglutide) and Mounjaro (tirzepatide) in England is markedly lower in areas with higher obesity prevalence, hinting at affordability barriers even as NHS access is expanded. The article discusses the potential impact on health inequalities and emphasizes the need for accompanying nutritional and behavioral support.

• Private access appears greater in less deprived areas, even after adjusting for obesity prevalence.
• NHS rollout criteria and the phased primary care access may leave many eligible people waiting years.
• Longer-term costs and the need for ongoing support could widen gaps between those who can pay and those who cannot.
• Policy implications point to addressing underlying determinants of obesity and ensuring equitable access to maintenance care.

Author: The Conversation

Introduction

The article analyzes private prescribing data for GLP-1 receptor agonists and tirzepatide, noting a troubling regional and socioeconomic divide in England. It contextualizes the potential for substantial weight loss demonstrated in clinical trials with semaglutide and tirzepatide, and then questions whether affordability is shaping real-world access as NHS access expands.

Weight-loss therapies and trial evidence

Wegovy (semaglutide) and Mounjaro (tirzepatide) act on GLP-1 and GIP pathways, respectively. Trials in adults without diabetes show meaningful weight reduction, with semaglutide achieving about 14.9% weight loss over 68 weeks and tirzepatide achieving up to 20.9% weight loss over 72 weeks, with diet and physical activity support included in trials.

England data on private prescribing and deprivation

In a 2026 analysis of 113,630 patients, private prescribing was 32% lower in England’s most deprived areas compared with the least deprived. After accounting for obesity prevalence, the estimated prescribing rate per person living with obesity was 120% higher in the least deprived areas. The study cannot prove cost causes the difference since it uses a single provider and uses postcodes as proxies for deprivation, but the association aligns with affordability influencing access.

NHS access is being phased in

NICE guidance recommends tirzepatide for adults with BMI at least 35 and weight-related conditions, with lower BMI thresholds for some ethnic groups. NHS England estimates around 3.4 million adults meet NICE criteria. Tirzepatide is available via specialist weight-management services for eligible patients, while primary-care access is narrower and rollout is staged. The initial primary-care rollout is expected to cover about 220,000 people in its first three years, with a funding variation that could extend to 12 years to make treatment available to the full eligible population.

Private prescriptions as another route and potential implications

Private prescriptions provide another route for those who can afford it, and the analysis suggests affordability could be a factor in uptake differences across areas. As NHS access matures, individuals with private means may access these medications sooner, potentially widening health inequalities unless publicly funded access expands rapidly and adequately supports necessary accompanying care.

Maintenance costs and support needs

Longer-term maintenance concerns arise if stopping therapy leads to weight regain; a 2026 systematic review found participants regained roughly 60% of weight within a year after stopping GLP-1 receptor agonists. The article notes that continued treatment or a maintenance plan may be needed, with nutritional and behavioral support recommended alongside prescriptions to mitigate risks such as nutritional deficiencies and muscle loss. For those paying privately, ongoing costs could be substantial, underscoring the importance of comprehensive support and monitoring.

Policy and health-equity implications

While NHS access is being phased in, the data illustrate how affordability can influence access to obesity treatments and potentially widen disparities. The article argues that addressing systemic causes of obesity and ensuring equitable access to maintenance support are crucial to prevent worsening health inequalities as the public-health impact of these therapies unfolds.